menu
    • menu
    [{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Astellas Pharma"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Reldesemtiv

    Menu

    Reldesemtiv

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytokinetics

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

                            Details : Reldesemtiv is an investigational, selective, small molecule fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program.

                            Product Name : CK-2127107

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 10, 2022

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytokinetics

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

                            Details : Reldesemtiv (CK-2127107), is an investigational, selective, small molecule fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program.

                            Product Name : CK-2127107

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cytokinetics

                            U.S.A arrow
                            Bioequity Europe
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            Bioequity Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

                            Details : CK-2127107 (Reldesemtiv) investigational, selective, small molecule fast skeletal muscle troponin activator arising from Cytokinetics’ skeletal muscle contractility, was designed to slow rate of calcium release from regulatory troponin complex of fast ...

                            Product Name : CK-2127107

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 16, 2022

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytokinetics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Astellas Terminates $450M+ Cytokinetics Pact

                            Details : The primary objective of the collaboration was to advance novel therapies for diseases and medical conditions associated with muscle weakness. In addition, Astellas had an exclusive license to co-develop Cytokinetics' drug candidate CK-2127107 in certain...

                            Product Name : CK-2127107

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 05, 2021

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cytokinetics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Cytokinetics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Scle...

                            Details : Cytokinetics is developing reldesemtiv, as a potential treatment for people with ALS, SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness or fatigue.

                            Product Name : CK-2127107

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 03, 2020

                            Lead Product(s) : Reldesemtiv

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth